Agonist
Back to library
MetabolicSubcutaneous

Adipotide

Also known as: FTPP · Fat-Targeted Proapoptotic Peptide · CKGGRAKDC-GG-D(KLAKLAK)2

Bifunctional peptidomimetic. The CKGGRAKDC domain binds prohibitin-1 on the vasculature of white adipose tissue; the D(KLAKLAK)2 domain disrupts mitochondrial membranes once internalized. Net effect is targeted apoptosis of adipose vasculature and rapid fat loss in primates.

At a glance

Half-life
4 hours
Common route
Subcutaneous
Typical dose range
1,000–3,000mcg
Stability (reconstituted)
14days refrigerated

Best timing

Limited human data. Primate protocols dosed daily for 28 days; rodent protocols dosed daily for 1–4 weeks. No established human dosing guidelines.

Contraindications

  • Renal disease (renal injury reported in primate studies — dose-limiting toxicity)
  • Pregnancy
  • Active cancer
  • No human clinical trial data — pre-clinical only

Watch symptoms

  • Renal toxicity — kidney function should be monitored closely
  • Dehydration
  • Rapid weight loss
  • Limited human pharmacokinetic and safety data — most evidence is from monkey studies

Citations

The primary literature.

  1. 01Reversal of obesity by targeted ablation of adipose tissue (Adipotide in primates)PubMed
  2. 02Reversal of diet-induced obesity by adipotide-mediated targeted vasculature ablationPubMed
Back to library